Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00568802

A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients

Sponsor: Stanford University

Interventions Hydroxyurea Placebo to match hydroxyurea

Updated 9 times since 2017 Last updated: Sep 11, 2019 Started: Jan 31, 2004 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00568802, this PHASE1/PHASE2 trial focuses on Muscular Atrophy, Spinal and remains completed. Sponsored by Stanford University, it has been updated 9 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1_PHASE2

▶ Show 4 earlier versions

Nov 2019 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Oct 2019 — Nov 2019 [monthly]

Completed PHASE1_PHASE2

Status: Unknown Status → Completed
Jun 2018 — Oct 2019 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States